Department of Biomedical Engineering, Faculty of Fundamental Problems of Technology, Wroclaw University of Science and Technology, Wybrzeże Stanisława Wyspiańskiego 27, Wrocław 50-370, Poland.
Nuffield Department of Women's and Reproductive Health, Medical Science Division, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DU, UK.
Drug Discov Today. 2020 Jul;25(7):1245-1252. doi: 10.1016/j.drudis.2020.04.018. Epub 2020 May 1.
To date, various chemically synthesized and biosynthesized nanoparticles, or hybrid nanosystems and/or nanoplatforms, have been developed under the umbrella of nanomedicine. These can be introduced into the body orally, nasally, intratumorally or intravenously. Successfully translating hybrid nanoplatforms from preclinical proof-of-concept to therapeutic value in the clinic is challenging. Having made significant advances with drug delivery technologies, we must learn from other areas of oncology drug development, where patient stratification and target-driven design have improved patient outcomes. This review aims to identify gaps in our understanding of the current strengths of nanomedicine platforms in drug delivery and cancer theranostics. We report on the current approaches of nanomedicine at preclinical and clinical stages.
迄今为止，各种化学合成和生物合成的纳米粒子、或杂化纳米系统和/或纳米平台，已在纳米医学的范畴下被开发出来。这些纳米材料可以通过口服、鼻内、瘤内或静脉内途径被引入体内。成功地将杂化纳米平台从临床前概念验证转化为临床治疗价值具有挑战性。在药物输送技术方面取得了重大进展的同时，我们必须从肿瘤药物开发的其他领域吸取经验，在这些领域中，患者分层和靶向设计已经改善了患者的治疗效果。本综述旨在确定我们对当前药物输送和癌症治疗中纳米医学平台优势的理解差距。我们报告了纳米医学在临床前和临床阶段的当前方法。
